| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
Ginkgoneolic acid targets PI3Kδ, a key enzyme in the PI3K/Akt/mTOR signaling pathway. By inhibiting PI3Kδ, it may modulate various cellular processes, including inflammation and cell survival. It also has antibacterial and anti-parasitic targets, though the specific molecular targets are not detailed.
|
|---|---|
| ln Vitro |
In vitro, Ginkgoneolic acid inhibits PI3Kδ with an IC50 of 2.49 μM. It also inhibits mast cell degranulation with an IC50 of 2.40 μM. It exhibits antibacterial activity against Streptococcus mutans, inhibiting its growth, acidogenicity, adherence, and biofilm formation. It also shows anti-parasitic activity.
|
| ln Vivo |
In vivo, Ginkgoneolic acid has been shown to have antibacterial and anti-parasitic activities. It has been tested for its effects on the growth of Mycobacterium tuberculosis in vivo, but it showed no significant therapeutic effect in mice and guinea pigs. This suggests limited in vivo efficacy for this particular indication.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for Ginkgoneolic acid involve measuring its inhibition of PI3Kδ enzymatic activity. These assays typically use purified PI3Kδ enzyme and appropriate substrates to determine the IC50 value. Its inhibition of mast cell degranulation is assessed using cell-based functional assays.
|
| Cell Assay |
In vitro cell-based assays for Ginkgoneolic acid include studying its effects on mast cell degranulation. Mast cells are treated with the compound, and the release of degranulation markers is measured. Its antibacterial activity is assessed using bacterial cultures, where its effects on growth, acidogenicity, adherence, and biofilm formation are evaluated.
|
| Animal Protocol |
In vivo animal experiments for Ginkgoneolic acid have been conducted in mice and guinea pigs to test its efficacy against tuberculosis. The compound was administered to infected animals, and its effect on the course of infection was monitored. However, it showed no significant therapeutic effect in these models.
|
| ADME/Pharmacokinetics |
Ginkgoneolic acid has a molecular weight of 320.47 and a molecular formula of C20H32O3. Specific pharmacokinetic data, such as absorption, distribution, metabolism, and excretion, are not detailed in the available sources. Its use in research suggests it is administered via various routes.
|
| Toxicity/Toxicokinetics |
Ginkgolic acids, including Ginkgoneolic acid, are known to be the main allergens in Ginkgo biloba extracts. Their structure is similar to urushiol, the sensitizing substance in lacquer. The more double bonds in the hydrocarbon chain, the more sensitizing they are. This indicates a potential for allergic reactions.
|
| References | |
| Additional Infomation |
2-Hydroxy-6-tridecylbenzoic acid is a hydroxybenzoic acid whose function is related to that of salicylic acid. It has been reported that 2-hydroxy-6-tridecylbenzoic acid exists in sea anemones (Caulocystis cephalornithos) and ginkgo (Ginkgo biloba), and relevant data are available for reference.
Ginkgoneolic acid is a natural compound found in Ginkgo biloba. It is a PI3Kδ inhibitor with antibacterial and anti-parasitic activities. However, it is also known to be a sensitizing agent and a major allergen in Ginkgo biloba extracts. It has shown limited in vivo efficacy against tuberculosis. |
| Molecular Formula |
C20H32O3
|
|---|---|
| Molecular Weight |
320.47
|
| Exact Mass |
320.235
|
| CAS # |
20261-38-5
|
| Related CAS # |
Ginkgolic Acid;22910-60-7
|
| PubChem CID |
161306
|
| Appearance |
White to off-white solid powder
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
449.5±33.0 °C at 760 mmHg
|
| Melting Point |
85 - 86 °C
|
| Flash Point |
239.8±21.9 °C
|
| Vapour Pressure |
0.0±1.2 mmHg at 25°C
|
| Index of Refraction |
1.519
|
| LogP |
8.9
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
23
|
| Complexity |
303
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
VEPUCZUJLKAVNM-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H32O3/c1-2-3-4-5-6-7-8-9-10-11-12-14-17-15-13-16-18(21)19(17)20(22)23/h13,15-16,21H,2-12,14H2,1H3,(H,22,23)
|
| Chemical Name |
2-hydroxy-6-tridecylbenzoic acid
|
| Synonyms |
6-n-TDSCA 6-n-Tridecylsalicylic acidAR1E2490 AR-1E2490AR 1E2490HY-N0078 HY N0078HYN0078
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~312.04 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.80 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1204 mL | 15.6021 mL | 31.2042 mL | |
| 5 mM | 0.6241 mL | 3.1204 mL | 6.2408 mL | |
| 10 mM | 0.3120 mL | 1.5602 mL | 3.1204 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
